Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders

H. J. Kim, Michael Camilleri, P. J. Carlson, F. Cremonini, I. Ferber, D. Stephens, S. McKinzie, A. R. Zinsmeister, R. Urrutia

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Background: The role of genetics in the phenotypic manifestations of irritable bowel syndrome (IBS) is unclear. Our aims were: (1) to compare the prevalence of polymorphisms of alpha 2 (α2) adrenoceptors, norepinephrine transporter, and serotonin transporter protein (soluble carrier protein member 4 (SLC6A4)) promoter in patients with lower functional gastrointestinal disorders (FGID) and in healthy controls; and (2) to test associations of these genetic variations with symptoms of IBS and high somatic symptom scores. Methods: Validated bowel and somatic symptom questionnaires characterised the phenotype: 90 with IBS constipation (IBS-C), 128 IBS diarrhoea, 38 IBS alternating bowel function, and 20 chronic abdominal pain. Logistic regression analyses assessed associations of different polymorphisms for α2 adrenoceptor and SLC6A4 with IBS or chronic abdominal pain phenotypes and high somatic score. Results: Two distinct polymorphisms independently appeared to be associated with the phenotype IBS-C: α2C Del 322-325 (odds ratio (OR) 2.48 (95% confidence interval (CI) 0.98, 6.28); p = 0.05) and α2A -1291 (C→G) (OR 1.66 (95% CI 0.94, 2.92); p = 0.08) relative to wild-type. Overall, the α2C Del 322-325 polymorphism (alone or combined with other polymorphisms) was also significantly associated with a high somatic symptom score (OR 2.2 (95% CI 1.06, 4.64); p = 0.03). Combinations of polymorphisms were also associated with high somatic scores. Conclusion: Functionally distinct α2A and α2C adrenoceptor and serotonin transporter polymorphisms are associated with constipation and high somatic symptoms in patients with lower functional gastrointestinal disorders, although the strength of the genetic contribution to the phenotype is unclear.

Original languageEnglish (US)
Pages (from-to)829-837
Number of pages9
JournalGut
Volume53
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Irritable Bowel Syndrome
Gastrointestinal Diseases
Constipation
Adrenergic Receptors
Phenotype
Odds Ratio
Confidence Intervals
Chronic Pain
Abdominal Pain
Norepinephrine Plasma Membrane Transport Proteins
Medically Unexplained Symptoms
Diarrhea
Carrier Proteins
Logistic Models
Regression Analysis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. / Kim, H. J.; Camilleri, Michael; Carlson, P. J.; Cremonini, F.; Ferber, I.; Stephens, D.; McKinzie, S.; Zinsmeister, A. R.; Urrutia, R.

In: Gut, Vol. 53, No. 6, 06.2004, p. 829-837.

Research output: Contribution to journalArticle

Kim, H. J. ; Camilleri, Michael ; Carlson, P. J. ; Cremonini, F. ; Ferber, I. ; Stephens, D. ; McKinzie, S. ; Zinsmeister, A. R. ; Urrutia, R. / Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. In: Gut. 2004 ; Vol. 53, No. 6. pp. 829-837.
@article{8ce8e6dac50a4c6a825fa000c1ce46af,
title = "Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders",
abstract = "Background: The role of genetics in the phenotypic manifestations of irritable bowel syndrome (IBS) is unclear. Our aims were: (1) to compare the prevalence of polymorphisms of alpha 2 (α2) adrenoceptors, norepinephrine transporter, and serotonin transporter protein (soluble carrier protein member 4 (SLC6A4)) promoter in patients with lower functional gastrointestinal disorders (FGID) and in healthy controls; and (2) to test associations of these genetic variations with symptoms of IBS and high somatic symptom scores. Methods: Validated bowel and somatic symptom questionnaires characterised the phenotype: 90 with IBS constipation (IBS-C), 128 IBS diarrhoea, 38 IBS alternating bowel function, and 20 chronic abdominal pain. Logistic regression analyses assessed associations of different polymorphisms for α2 adrenoceptor and SLC6A4 with IBS or chronic abdominal pain phenotypes and high somatic score. Results: Two distinct polymorphisms independently appeared to be associated with the phenotype IBS-C: α2C Del 322-325 (odds ratio (OR) 2.48 (95{\%} confidence interval (CI) 0.98, 6.28); p = 0.05) and α2A -1291 (C→G) (OR 1.66 (95{\%} CI 0.94, 2.92); p = 0.08) relative to wild-type. Overall, the α2C Del 322-325 polymorphism (alone or combined with other polymorphisms) was also significantly associated with a high somatic symptom score (OR 2.2 (95{\%} CI 1.06, 4.64); p = 0.03). Combinations of polymorphisms were also associated with high somatic scores. Conclusion: Functionally distinct α2A and α2C adrenoceptor and serotonin transporter polymorphisms are associated with constipation and high somatic symptoms in patients with lower functional gastrointestinal disorders, although the strength of the genetic contribution to the phenotype is unclear.",
author = "Kim, {H. J.} and Michael Camilleri and Carlson, {P. J.} and F. Cremonini and I. Ferber and D. Stephens and S. McKinzie and Zinsmeister, {A. R.} and R. Urrutia",
year = "2004",
month = "6",
doi = "10.1136/gut.2003.030882",
language = "English (US)",
volume = "53",
pages = "829--837",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Association of distinct α2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders

AU - Kim, H. J.

AU - Camilleri, Michael

AU - Carlson, P. J.

AU - Cremonini, F.

AU - Ferber, I.

AU - Stephens, D.

AU - McKinzie, S.

AU - Zinsmeister, A. R.

AU - Urrutia, R.

PY - 2004/6

Y1 - 2004/6

N2 - Background: The role of genetics in the phenotypic manifestations of irritable bowel syndrome (IBS) is unclear. Our aims were: (1) to compare the prevalence of polymorphisms of alpha 2 (α2) adrenoceptors, norepinephrine transporter, and serotonin transporter protein (soluble carrier protein member 4 (SLC6A4)) promoter in patients with lower functional gastrointestinal disorders (FGID) and in healthy controls; and (2) to test associations of these genetic variations with symptoms of IBS and high somatic symptom scores. Methods: Validated bowel and somatic symptom questionnaires characterised the phenotype: 90 with IBS constipation (IBS-C), 128 IBS diarrhoea, 38 IBS alternating bowel function, and 20 chronic abdominal pain. Logistic regression analyses assessed associations of different polymorphisms for α2 adrenoceptor and SLC6A4 with IBS or chronic abdominal pain phenotypes and high somatic score. Results: Two distinct polymorphisms independently appeared to be associated with the phenotype IBS-C: α2C Del 322-325 (odds ratio (OR) 2.48 (95% confidence interval (CI) 0.98, 6.28); p = 0.05) and α2A -1291 (C→G) (OR 1.66 (95% CI 0.94, 2.92); p = 0.08) relative to wild-type. Overall, the α2C Del 322-325 polymorphism (alone or combined with other polymorphisms) was also significantly associated with a high somatic symptom score (OR 2.2 (95% CI 1.06, 4.64); p = 0.03). Combinations of polymorphisms were also associated with high somatic scores. Conclusion: Functionally distinct α2A and α2C adrenoceptor and serotonin transporter polymorphisms are associated with constipation and high somatic symptoms in patients with lower functional gastrointestinal disorders, although the strength of the genetic contribution to the phenotype is unclear.

AB - Background: The role of genetics in the phenotypic manifestations of irritable bowel syndrome (IBS) is unclear. Our aims were: (1) to compare the prevalence of polymorphisms of alpha 2 (α2) adrenoceptors, norepinephrine transporter, and serotonin transporter protein (soluble carrier protein member 4 (SLC6A4)) promoter in patients with lower functional gastrointestinal disorders (FGID) and in healthy controls; and (2) to test associations of these genetic variations with symptoms of IBS and high somatic symptom scores. Methods: Validated bowel and somatic symptom questionnaires characterised the phenotype: 90 with IBS constipation (IBS-C), 128 IBS diarrhoea, 38 IBS alternating bowel function, and 20 chronic abdominal pain. Logistic regression analyses assessed associations of different polymorphisms for α2 adrenoceptor and SLC6A4 with IBS or chronic abdominal pain phenotypes and high somatic score. Results: Two distinct polymorphisms independently appeared to be associated with the phenotype IBS-C: α2C Del 322-325 (odds ratio (OR) 2.48 (95% confidence interval (CI) 0.98, 6.28); p = 0.05) and α2A -1291 (C→G) (OR 1.66 (95% CI 0.94, 2.92); p = 0.08) relative to wild-type. Overall, the α2C Del 322-325 polymorphism (alone or combined with other polymorphisms) was also significantly associated with a high somatic symptom score (OR 2.2 (95% CI 1.06, 4.64); p = 0.03). Combinations of polymorphisms were also associated with high somatic scores. Conclusion: Functionally distinct α2A and α2C adrenoceptor and serotonin transporter polymorphisms are associated with constipation and high somatic symptoms in patients with lower functional gastrointestinal disorders, although the strength of the genetic contribution to the phenotype is unclear.

UR - http://www.scopus.com/inward/record.url?scp=2442677620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442677620&partnerID=8YFLogxK

U2 - 10.1136/gut.2003.030882

DO - 10.1136/gut.2003.030882

M3 - Article

C2 - 15138209

AN - SCOPUS:2442677620

VL - 53

SP - 829

EP - 837

JO - Gut

JF - Gut

SN - 0017-5749

IS - 6

ER -